Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
Identifieur interne : 002D75 ( Main/Exploration ); précédent : 002D74; suivant : 002D76Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
Auteurs : Frédéric Calon [Canada] ; Ali H. Rajput ; Oleh Hornykiewicz ; Paul J. Bédard ; Thérèse Di PaoloSource :
- Neurobiology of disease [ 0969-9961 ] ; 2003.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Binding Sites (drug effects), Binding Sites (physiology), Binding, Competitive (drug effects), Binding, Competitive (physiology), Brain (drug effects), Brain (metabolism), Brain (physiopathology), Dopamine (deficiency), Dopamine Plasma Membrane Transport Proteins, Dyskinesia, Drug-Induced (metabolism), Dyskinesia, Drug-Induced (physiopathology), Excitatory Amino Acid Antagonists (pharmacology), Female, Humans, Levodopa (adverse effects), Levodopa (pharmacology), Male, Membrane Glycoproteins, Membrane Transport Proteins (deficiency), Nerve Tissue Proteins, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Radioligand Assay, Receptors, N-Methyl-D-Aspartate (drug effects), Receptors, N-Methyl-D-Aspartate (metabolism), alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (pharmacology).
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , deficiency : Dopamine, Membrane Transport Proteins.
- drug effects : Binding Sites, Binding, Competitive, Brain, Receptors, N-Methyl-D-Aspartate.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Dyskinesia, Drug-Induced, Parkinson Disease, Receptors, N-Methyl-D-Aspartate.
- chemical , pharmacology : Excitatory Amino Acid Antagonists, Levodopa, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid.
- physiology : Binding Sites, Binding, Competitive.
- physiopathology : Brain, Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Aged, 80 and over, Dopamine Plasma Membrane Transport Proteins, Female, Humans, Male, Membrane Glycoproteins, Nerve Tissue Proteins, Radioligand Assay.
Abstract
Glutamate receptors were studied in the brains of controls and Parkinson's disease (PD) patients, of which 10 of 14 developed motor complications (dyskinesias and/or wearing-off) following levodopa therapy. (125)I-RTI binding to the dopamine transporter and dopamine concentrations show comparable nigrostriatal denervation between the subgroups of PD patients. (3)H-Ro 25-6981 binding to the NR1/NR2B NMDA receptor was increased in the putamen of PD patients experiencing motor complications compared to those who did not (+53%) and compared to controls (+18%) whereas binding remained unchanged in the caudate nucleus. (3)H-AMPA binding was increased in the lateral putamen (+23%) of PD patients with motor complications compared to those without whereas it was decreased in the caudate nucleus of the PD patients (-16%) compared to controls. Caudate and putamen (3)H-CGP39653 binding to NR1/NR2A NMDA receptor and NR1 subunit mRNA levels measured by in situ hybridization were unchanged in subgroups of PD patients compared to controls. These findings suggest that glutamate receptor supersensitivity in the putamen plays a role in the development of motor complications (both wearing-Off and dyskinesias) following long-term levodopa therapy in PD.
PubMed: 14678757
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001401
- to stream PubMed, to step Curation: 001401
- to stream PubMed, to step Checkpoint: 001401
- to stream Ncbi, to step Merge: 000380
- to stream Ncbi, to step Curation: 000380
- to stream Ncbi, to step Checkpoint: 000380
- to stream Main, to step Merge: 003161
- to stream Main, to step Curation: 002D75
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.</title><author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H" last="Rajput">Ali H. Rajput</name></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J" last="Bédard">Paul J. Bédard</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14678757</idno><idno type="pmid">14678757</idno><idno type="wicri:Area/PubMed/Corpus">001401</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001401</idno><idno type="wicri:Area/PubMed/Curation">001401</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001401</idno><idno type="wicri:Area/PubMed/Checkpoint">001401</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001401</idno><idno type="wicri:Area/Ncbi/Merge">000380</idno><idno type="wicri:Area/Ncbi/Curation">000380</idno><idno type="wicri:Area/Ncbi/Checkpoint">000380</idno><idno type="wicri:doubleKey">0969-9961:2003:Calon F:levodopa:induced:motor</idno><idno type="wicri:Area/Main/Merge">003161</idno><idno type="wicri:Area/Main/Curation">002D75</idno><idno type="wicri:Area/Main/Exploration">002D75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.</title><author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H" last="Rajput">Ali H. Rajput</name></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J" last="Bédard">Paul J. Bédard</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="ISSN">0969-9961</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Binding Sites (drug effects)</term><term>Binding Sites (physiology)</term><term>Binding, Competitive (drug effects)</term><term>Binding, Competitive (physiology)</term><term>Brain (drug effects)</term><term>Brain (metabolism)</term><term>Brain (physiopathology)</term><term>Dopamine (deficiency)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Dyskinesia, Drug-Induced (metabolism)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Excitatory Amino Acid Antagonists (pharmacology)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins (deficiency)</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (physiopathology)</term><term>Radioligand Assay</term><term>Receptors, N-Methyl-D-Aspartate (drug effects)</term><term>Receptors, N-Methyl-D-Aspartate (metabolism)</term><term>alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term><term>Membrane Transport Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Binding Sites</term><term>Binding, Competitive</term><term>Brain</term><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term><term>Levodopa</term><term>alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Binding Sites</term><term>Binding, Competitive</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Female</term><term>Humans</term><term>Male</term><term>Membrane Glycoproteins</term><term>Nerve Tissue Proteins</term><term>Radioligand Assay</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Glutamate receptors were studied in the brains of controls and Parkinson's disease (PD) patients, of which 10 of 14 developed motor complications (dyskinesias and/or wearing-off) following levodopa therapy. (125)I-RTI binding to the dopamine transporter and dopamine concentrations show comparable nigrostriatal denervation between the subgroups of PD patients. (3)H-Ro 25-6981 binding to the NR1/NR2B NMDA receptor was increased in the putamen of PD patients experiencing motor complications compared to those who did not (+53%) and compared to controls (+18%) whereas binding remained unchanged in the caudate nucleus. (3)H-AMPA binding was increased in the lateral putamen (+23%) of PD patients with motor complications compared to those without whereas it was decreased in the caudate nucleus of the PD patients (-16%) compared to controls. Caudate and putamen (3)H-CGP39653 binding to NR1/NR2A NMDA receptor and NR1 subunit mRNA levels measured by in situ hybridization were unchanged in subgroups of PD patients compared to controls. These findings suggest that glutamate receptor supersensitivity in the putamen plays a role in the development of motor complications (both wearing-Off and dyskinesias) following long-term levodopa therapy in PD.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J" last="Bédard">Paul J. Bédard</name><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H" last="Rajput">Ali H. Rajput</name></noCountry><country name="Canada"><noRegion><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:14678757
|texte= Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:14678757" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |